

Application No.: 10/518,554

Docket No.: 2815-0287PUS1

AMENDED CLAIM SET:

RECEIVED
CENTRAL FAX CENTER
OCT 27 2006

1. – 28. (cancelled).

29. (previously presented) A 1,5-disubstituted benzimidazol-2-one compound, which is 1-(5-chloro-2-hydroxyphenyl)-5-chloro-1,3-dihydro-2H-benzimidazo-2-one; or a pharmaceutically-acceptable salt thereof.

30. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of the 1,5-disubstituted benzimidazol-2-one compound of claim 29, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent.

31. (previously presented) The pharmaceutical composition of claim 30, which composition also comprises a chemotherapeutic agent.

32. (currently amended) A method of increasing the blood-brain barrier permeability of a mammal, including a human, which method comprises the step of administering to such a living animal body in need thereof, a therapeutically effective amount of a 1,5-disubstituted benzimidazol-2-one compound of claim 29, or a pharmaceutically-acceptable salt thereof.

33. – 36. (cancelled).

Application No.: 10/518,554

Docket No.: 2815-0287PUS1

37. (previously presented) The method according to claim 32, which method comprises co-administration of a chemotherapeutic agent.

38. – 40. (cancelled).

41. (previously presented) A kit-of-parts useful for enhancing the delivery of a medicament to the brain, which kit comprises:

the 1,5-disubstituted benzimidazol-2-one compound of claim 29;

a chemotherapeutic agent; and

instructions for using the 1,5-disubstituted benzimidazol-2-one compound for enhancing delivery of the chemotherapeutic agent to the brain.